These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

152 related items for PubMed ID: 2173410

  • 1. Vimentin is preferentially expressed in high-grade ductal and medullary, but not in lobular breast carcinomas.
    Domagala W, Woźniak L, Lasota J, Weber K, Osborn M.
    Am J Pathol; 1990 Nov; 137(5):1059-64. PubMed ID: 2173410
    [Abstract] [Full Text] [Related]

  • 2. Vimentin expression in different types of breast carcinoma immunohistochemical study.
    Essa TM, el Tatawi FA, Hamdi KN, Arafa WA.
    J Egypt Soc Parasitol; 1996 Aug; 26(2):433-42. PubMed ID: 8754651
    [Abstract] [Full Text] [Related]

  • 3. Nuclear p53 protein accumulates preferentially in medullary and high-grade ductal but rarely in lobular breast carcinomas.
    Domagala W, Harezga B, Szadowska A, Markiewski M, Weber K, Osborn M.
    Am J Pathol; 1993 Mar; 142(3):669-74. PubMed ID: 8384406
    [Abstract] [Full Text] [Related]

  • 4. Vimentin is preferentially expressed in human breast carcinomas with low estrogen receptor and high Ki-67 growth fraction.
    Domagala W, Lasota J, Bartkowiak J, Weber K, Osborn M.
    Am J Pathol; 1990 Jan; 136(1):219-27. PubMed ID: 2153347
    [Abstract] [Full Text] [Related]

  • 5. Vimentin expression appears to be associated with poor prognosis in node-negative ductal NOS breast carcinomas.
    Domagala W, Lasota J, Dukowicz A, Markiewski M, Striker G, Weber K, Osborn M.
    Am J Pathol; 1990 Dec; 137(6):1299-304. PubMed ID: 1701960
    [Abstract] [Full Text] [Related]

  • 6. Cathepsin D in invasive ductal NOS breast carcinoma as defined by immunohistochemistry. No correlation with survival at 5 years.
    Domagala W, Striker G, Szadowska A, Dukowicz A, Weber K, Osborn M.
    Am J Pathol; 1992 Nov; 141(5):1003-12. PubMed ID: 1332483
    [Abstract] [Full Text] [Related]

  • 7. The role of HER2/neu overexpression/amplification in the progression of ductal carcinoma in situ to invasive carcinoma of the breast.
    Latta EK, Tjan S, Parkes RK, O'Malley FP.
    Mod Pathol; 2002 Dec; 15(12):1318-25. PubMed ID: 12481013
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Should histologic type be taken into account when considering neoadjuvant chemotherapy in breast carcinoma?
    Sullivan PS, Apple SK.
    Breast J; 2009 Dec; 15(2):146-54. PubMed ID: 19292800
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Vascular stroma formation in carcinoma in situ, invasive carcinoma, and metastatic carcinoma of the breast.
    Brown LF, Guidi AJ, Schnitt SJ, Van De Water L, Iruela-Arispe ML, Yeo TK, Tognazzi K, Dvorak HF.
    Clin Cancer Res; 1999 May; 5(5):1041-56. PubMed ID: 10353737
    [Abstract] [Full Text] [Related]

  • 13. p53 mutations and histological type of invasive breast carcinoma.
    Marchetti A, Buttitta F, Pellegrini S, Campani D, Diella F, Cecchetti D, Callahan R, Bistocchi M.
    Cancer Res; 1993 Oct 01; 53(19):4665-9. PubMed ID: 8402644
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Expression and amplification of cyclin D1 in primary breast carcinomas: relationship with histopathological types and clinico-pathological parameters.
    Naidu R, Wahab NA, Yadav MM, Kutty MK.
    Oncol Rep; 2002 Oct 01; 9(2):409-16. PubMed ID: 11836618
    [Abstract] [Full Text] [Related]

  • 16. Paucity of fibronectin in invasive lobular carcinoma of breast.
    D'Ardenne AJ, Barnard NJ.
    J Pathol; 1989 Mar 01; 157(3):219-24. PubMed ID: 2538611
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Androgen receptors frequently are expressed in breast carcinomas: potential relevance to new therapeutic strategies.
    Moinfar F, Okcu M, Tsybrovskyy O, Regitnig P, Lax SF, Weybora W, Ratschek M, Tavassoli FA, Denk H.
    Cancer; 2003 Aug 15; 98(4):703-11. PubMed ID: 12910513
    [Abstract] [Full Text] [Related]

  • 20. Breast carcinoma in women 35 years and younger: a pathological study.
    Fernandopulle SM, Cher-Siangang P, Tan PH.
    Pathology; 2006 Jun 15; 38(3):219-22. PubMed ID: 16753742
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.